On Monday, the health and wellness platform Hims & Hers Health Inc ( HIMS ) shares traded higher after the company announced the addition of GLP-1 injections to its weight loss portfolio.

The company now offers access to GLP-1 injections and weight management oral medication kits. 

Access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Novo Nordisk A/S’s Ozempic and Wegovy without navigating the shortages and costs currently limiting access to the branded medications. 

Through a partnership with a US manufacturer of generic and 503B compounded injectable medications, Hims & Hers can help millions of obesity patients.

Hims & Hers expects its weight loss program to generate more than $100 million in revenue by the end of 2025.

GLP-1 injections are fulfilled and shipped from Hims & Hers’ affiliated pharmacies. 

Once consistent supply is available through the pharmacies’ wholesaler, Hims & Hers plans to make branded options available to customers, expanding the offering beyond the current oral medication kits and compounded GLP-1 injectable medications.

Weight loss medications are priced at $79/month for oral medication kits and $199/month for compounded GLP-1 injections. 

Pricing includes unlimited medical consultations with a licensed provider.

Oral medication kits and compounded GLP-1 injections are not available in all states.

Price Action: HIMS shares are up 34.9% at $19.65 at last check Monday.